Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.139
-0.001 (-0.13%)
At close: Feb 6, 2026, 4:00 PM EST
1.130
-0.009 (-0.75%)
After-hours: Feb 6, 2026, 6:25 PM EST
Rein Therapeutics Employees
Rein Therapeutics had 11 employees as of December 31, 2024. The number of employees decreased by 4 or -26.67% compared to the previous year.
Employees
11
Change (1Y)
-4
Growth (1Y)
-26.67%
Revenue / Employee
n/a
Profits / Employee
-$5,353,182
Market Cap
29.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 11 | -4 | -26.67% |
| Dec 31, 2023 | 15 | 9 | 150.00% |
| Dec 31, 2022 | 6 | -3 | -33.33% |
| Dec 31, 2021 | 9 | 1 | 12.50% |
| Dec 31, 2020 | 8 | -5 | -38.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Kyntra Bio | 225 |
| Barinthus Biotherapeutics | 105 |
| Passage Bio | 60 |
| Cue Biopharma | 41 |
| Werewolf Therapeutics | 39 |
| AN2 Therapeutics | 22 |
| NeuroSense Therapeutics | 17 |
| Outlook Therapeutics | 17 |
RNTX News
- 3 months ago - Why Is Rein Therapeutics Stock Trading Higher On Monday? - Benzinga
- 4 months ago - Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 5 months ago - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 6 months ago - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 6 months ago - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - GlobeNewsWire
- 8 months ago - Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - PRNewsWire
- 8 months ago - US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
- 9 months ago - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire